NCT00831714 - Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty | Biotech Hunter

Enrollment

19,076

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

April 30, 2013

Conditions

Venous Thromboembolism

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for VTE prophylaxis with Rivaroxaban has been made

DRUG

Standard care treatment for VTE prophylaxis

Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for a pharmacologic VTE prophylaxis treatment other than rivaroxaban has been made

Trial Locations (42)

Unknown

Many Locations